Halting tumor growth by interfering with tumor-induced angiogenesis is an attractive therapeutic approach. Such
Introduction
Blocking tumor-induced angiogenesis has emerged as an attractive therapeutic goal in cancer treatment and is increasingly exploited in the clinics (1, 2) . Notably in preclinical models, several approaches have shown high efficacy in blocking tumor angiogenesis and thus attenuating tumor growth. The angiogenic growth factor vascular endothelial growth factor (VEGF)-A has been found highly expressed in the majority of cancer types and to exert a key function during the so-called angiogenic switch (3) . Growth factors of the VEGF family signal through their cognate receptor tyrosine kinases, VEGF receptors (VEGFR) 1, 2, and 3 (4) . Many approaches to repress tumor angiogenesis target the VEGF pathway by either depleting the VEGF-A ligand with specific antibodies (bevacizumab) or using soluble VEGFR constructs (VEGF-Trap; ref. 3) . Another way to efficiently perturb VEGF-A signaling is to block the kinase activity of VEGFR-1 and -2 by small-molecule inhibitors, such as sorafenib, sunitinib, or PTK787/ZK222584 (PTK/ZK; refs. 5, 6) . The receptor tyrosine kinase inhibitor PTK/ZK has been shown previously to inhibit signal transduction by VEGFR-1, -2, and -3 in vitro and to repress angiogenesis by inhibiting human VEGFR-1 and -2 phosphorylation with very high efficacy (IC 50 , 0.037 and 0.077 Amol/L, respectively) and, to a lesser extent, murine VEGFR-2 and human VEGFR-3 (IC 50 , 0.27 and 0.66 Amol/L, respectively; ref. 7) .
Tumor lymphangiogenesis has been repeatedly shown to correlate with lymph node metastasis and poor prognosis in different types of cancer (8) . Thus, repression of tumor lymphangiogenesis by interfering with the activities of the lymphangiogenic factors VEGF-C and -D and their cognate receptor VEGFR-3 may be an attractive avenue to interfere with tumor progression and metastasis. Accordingly, many experimental mouse models of physiologic lymphangiogenesis and tumor lymphangiogenesis have been employed to test different approaches for repressing lymphangiogenesis. For example, small interfering RNAmediated depletion of VEGF-C expression or sequestration of VEGF-C and -D by soluble VEGFR-3 reduces tumor lymphangiogenesis and, to varying degrees, metastasis to lymph nodes and distant organs (9 -12) . Moreover, neutralizing antibodies against VEGFR-3 has lead to an efficient reduction in regenerative lymphangiogenesis, corneal lymphangiogenesis, and tumor lymphangiogenesis and metastasis (13 -17) . Finally, repression of inflammatory lymphangiogenesis and tumor lymphangiogenesis is also efficiently repressed by the pharmacologic inhibitors of VEGFR activity ZK261991, E7080, and indolinone derivatives (18 -20) . Recently, PTK/ZK has also been reported to inhibit tumor lymphangiogenesis in a syngeneic ear transplantation model of melanoma (21) .
We have here investigated the potential effect of PTK/ZK treatment on tumor progression in the Rip1Tag2 transgenic mouse model of stochastic pancreatic h cell carcinogenesis. In Rip1Tag2 transgenic mice, SV40 T antigen is expressed under the control of the rat insulin promoter in the h cells of pancreatic islets of Langerhans (22) . During tumor progression in Rip1Tag2 mice, early proliferating hyperplastic islets can be distinguished from hyperplastic islets that have undergone an ''angiogenic switch'' and started to induce angiogenesis (23) . These neoplastic lesions subsequently grow out as benign adenoma and eventually progress to invasive carcinoma. Metastasis rarely develops, because these mice succumb to insulinoma-induced hypoglycemia between ages 12 and 14 weeks. The angiogenic switch during Rip1Tag2 tumor progression has been extensively studied. VEGF-A is well known to play a critical role in the onset of tumor angiogenesis, and as expected, interfering with VEGF-A function, by genetic ablation of the VEGF-A gene, by adenoviral expression of soluble VEGFRs, or by pharmacologic interference, has resulted in impaired tumor angiogenesis and, with it, in reduced tumor growth (24 -27) .
Previously, we have reported that the transgenic expression of VEGF-C and VEGF-D in pancreatic h tumor cells of double-transgenic Rip1Tag2;Rip1VEGF-C and Rip1-Tag2;Rip1VEGF-D mice results in the induction of tumor lymphangiogenesis and metastatic spread to lymph nodes (VEGF-C) and to lymph nodes and lungs (VEGF-D; refs. 28, 29) . Moreover, ablation of the function of neural cell adhesion molecule (NCAM) during Rip1Tag2 tumor progression in Rip1Tag2;NCAM À/À mice induces the expression of VEGF-C and -D and, with it, up-regulated tumor-associated lymphangiogenesis and lymph node metastasis (30, 31) . Here, we report that treatment of these mouse models of tumor-associated lymphangiogenesis and lymphogenic metastasis with the VEGFR inhibitor PTK/ZK effectively inhibits tumor blood vessel angiogenesis and tumor growth but does not attenuate tumor lymphangiogenesis and metastasis to lymph nodes or lung. Moreover, although soluble VEGFR-3 represses tumor lymphangiogenesis in NCAM-deficient mice (30) , it fails to interfere with tumor lymphangiogenesis in VEGF-C transgenic Rip1Tag2 mice. Together, the results suggest that the timing and levels of VEGF-C and D expression are critical variables for interfering with VEGFR-mediated lymphangiogenesis and that active and ongoing tumor lymphangiogenesis may rely on additional signals other than the activation of VEGFR-3.
Materials and Methods

Mice
The generation and phenotypic analysis of Rip1Tag2, Rip1Tag2;Rip1VEGF-C, Rip1Tag2;Rip1VEGF-D, and Rip1Tag2;NCAM À/À transgenic mice has been described previously (22, 28, 29) . All mice were strictly kept in a C57BL/6 genetic background. PTK/ZK was kindly provided by Novartis Pharma. Mice were treated with either 100 mg/kg bodyweight PTK/ZK dissolved in polyethylene glycol 300 (PEG300; Sigma) or PEG300 alone by daily oral administration for 3 weeks starting at age 9 weeks. Recombinant E1/E3-defective adenovirus expressing soluble VEGFR-3 (AdsFlt-4) or EGFP (AdEGFP) was used as described previously (30) . For treatment of Rip1Tag2;Rip1-VEGF-C double-transgenic mice, 5 Â 10 9 virus particles were tail vein-injected once a week for 3 weeks. Mice were sacrificed and tumor growth and metastasis to distant organs were assessed. Tumor incidence per mouse was determined by counting all macroscopically detectable pancreatic tumors with a minimal diameter of 1 mm. Tumor volumes were calculated by measuring the tumor diameter and assuming a spherical shape of the tumors. All experimental procedures involving mice were done according to the guidelines of the Swiss Federal Veterinary Office and the regulations of the Cantonal Veterinary Office of Basel Stadt.
Histopathologic Analysis Pancreata from transgenic and control mice were isolated and fixed in 4% paraformaldehyde overnight, dehydrated, and embedded in paraffin. Freshly isolated tissue was embedded in OCT compound (Tissue-Tek) and snap frozen in liquid nitrogen. For analysis of cell proliferation, mice were i.p. injected with 100 Ag bromodeoxyuridine (Sigma)/ g bodyweight 90 min before sacrifice. Histologic analysis was done on H&E-stained paraffin sections. Histologic staging and grading of tumors and the quantification of tumor cell clusters circulating in lymphatic vessels were done in a blindfold manner on H&E-stained sections. For the analysis of lung metastasis in Rip1Tag2;Rip1VEGF-D mice, the entire lungs were cut into 10 Am sections and stained with H&E for microscopic examination. Lymph node metastases were detected by positive insulin staining of regional lymph nodes in pancreatic paraffin sections.
The following antibodies were used: rabbit anti-mouse LYVE-1 (Reliatech), rat anti-mouse CD31 (Pharmingen), rabbit anti-mouse NG2 (Chemicon), rat anti-mouse F4/80, biotinylated mouse anti-bromodeoxyuridine (Zymed), and rabbit anti-mouse caspase-3 (Calbiochem). The secondary antibodies used were either conjugated with Alexa Fluor 488 or 568 (Molecular Probes). Nuclei were counterstained with 4 ¶,6-diamidino-2-phenylindole.
CD31
+ intratumoral vessels and the numbers of cells positively staining for NG2 (pericytes), cleaved caspase-3 (apoptosis), and F4/80 (macrophages) were determined using ImageJ software (NIH). 3 Pericyte coverage of microvessels was determined by counting CD31 + /NG2 + vessels. All sections were analyzed with either an Axioskop 2 Plus light microscope using Axiovision 3.1. Software (Zeiss) or a Nikon Diaphot 300 immunofluorescence microscope (Nikon) using Openlab 3.1.7. Software (Improvision).
Phospho-VEGFR-3 ELISA For the quantification of phospho-VEGFR-3 in tumorassociated lymphatics, Rip1Tag2;Rip1VEGF-C mice were treated with either 100 mg/kg PTK/ZK or vehicle control for 3 weeks starting at age 9 weeks. At week 12, the mice (2 mice each) were sacrificed and macroscopically detectable tumors (5 per mouse) were excised and homogenized in ice-cold cell lysis buffer [1% NP-40, 20 mmol/L Tris (pH 8.0), 137 mmol/L NaCl, 10% glycerol, 2 mmol/L EDTA, 1 mmol/L activated sodium orthovanadate, 10 g/mL aprotinin, and 10 g/mL leupeptin]. After removal of cell debris by centrifugation, the protein contents of the cleared lysates were determined and normalized amounts of protein lysates were used for quantitative ELISA assays as recommended by the manufacturer (R&D Systems).
AlamarBlue BTumor Cell Proliferation Assay h insulinoma cells were seeded into 96-well plates at 7,000 per well in 150 AL DMEM/10% FCS at day -2. PTK787 was added at day 0. Medium was changed at days -1, 0, and 2. Metabolic activity of cells, representing proliferation, was measured by removing 75 AL medium and adding 10 AL AlamarBlue (AbD Serotec). Fluorescence was measured 5 h past-AlamarBlue addition at excitation wavelength of 560 nm and emission wavelength of 590 nm.
Results
P TK / ZK Imp air s Tumor Grow th an d Tumor Progression
We have investigated the effect of the small-molecule inhibitor PTK/ZK on VEGFR-driven tumor angiogenesis in vivo in the Rip1Tag2 mouse model of h cell carcinogenesis. During multistage tumorigenesis in Rip1Tag2 transgenic mice, VEGF-dependent angiogenesis is first detected in hyperplastic lesions of 6-week-old mice. After the onset of tumor angiogenesis, the neoplastic lesions progress to adenoma and carcinoma at age 12 weeks, when the mice are sacrificed to forestall death by hyperinsulinemia/hypoglycemia. In different studies, these mice were instrumental to show the success of VEGF blockade during tumor growth by pharmacologic and also by genetic means (24, 27, 32) . We assessed the efficacy of VEGFR inhibition by PTK/ZK during tumor angiogenesis and lymphangiogenesis in the Rip1Tag2 mouse model. Rip1Tag2 singletransgenic mice, double-transgenic Rip1Tag2;Rip1VEGF-C and Rip1Tag2;Rip1VEGF-D, and NCAM-deficient Rip1Tag2;NCAM À/À mice were treated daily with PTK/ ZK (100 mg/kg body weight) for 3 weeks starting at age 9 weeks, a time point at which tumor angiogenesis and tumor growth are most active in single-transgenic Rip1Tag2 mice and tumor lymphangiogenesis and lymph node metastasis are occurring in the composite VEGF-C/D transgenic or NCAM-deficient Rip1Tag2 mice. Histologic examination of tumor sections from PTK/ZK-treated and control-treated mice revealed that tumors of PTK/ZK-treated mice were smaller and showed large areas of internal hemorrhaging in comparison with controls (Fig. 1A) . Analysis of the total tumor volume in PTK/ZK-treated versus vehicletreated mice revealed a significant reduction in tumor burden per Rip1Tag2 mouse, which was also observed in Rip1Tag2;Rip1VEGF-C and Rip1Tag2;Rip1VEGF-D doubletransgenic mice (Fig. 1B) and Rip1Tag2;NCAM À/À mice (data nor shown). Moreover, a 1-week short-term treatment of late-stage 12-week-old Rip1Tag2 transgenic mice also diminished the total tumor volumes when compared with control-treated mice (Fig. 1B) .
Tumor incidence, as determined by the number of tumors with a diameter >1 mm, was also significantly reduced by the treatment with PTK/ZK ( Fig. 2A) . Furthermore, histopathologic staging (33) of h cell tumors in PTK/ZK-treated mice revealed that the ratio of epithelial, differentiated adenomas to invasive carcinomas was increased in comparison with control-treated animals, showing that PTK/ZK treatment retarded tumor progression in Rip1Tag2 mice (Fig. 2B) . Treatment of Rip1Tag2 mice with PTK/ZK resulted in a significant increase of apoptotic cells within tumors as visualized by immunofluorescence staining for cleaved caspase-3 (Fig. 2C) . However, tumor cell proliferation was unaffected by PTK/ZK treatment as determined by bromodeoxyuridine incorporation assays (Fig. 2D) . Together, these results show that PTK/ZK impairs tumor growth and tumor progression in Rip1Tag2 transgenic mice by affecting tumor cell survival but not tumor cell proliferation. To exclude a direct toxic effect of PTK/ZK on h tumor cells, cultured h tumor cell lines established from Rip1Tag2 transgenic mice were treated with PTK/ZK at increasing doses. Cell proliferation was not significantly affected at the doses comparable with the in vivo therapeutic regimen, and only at the highest dose of 10 Amol/L final concentration h tumor cell proliferation was diminished (Fig. 3) .
PTK/ZK Efficiently RepressesTumor Angiogenesis Because PTK/ZK is known to inhibit VEGFR-mediated signal transduction in endothelial cells, we analyzed tumor microvessel density in PTK/ZK-treated versus vehicletreated mice by determining the number of CD31 + intratumoral blood vessels. As shown in Fig. 4 , blood vessel densities in PTK/ZK-treated tumors were significantly reduced when compared with control-treated tumors. Moreover, together with the reduction in CD31 + intratumoral blood vessels, the overall number of NG2 + pericytes was significantly diminished in PTK/ZK-treated compared with control-treated tumors (Fig. 4A) . This decline in the number of NG2 + pericytes was comparable with the observed decrease in CD31 + blood vessels. However, the number of CD31 + vessels covered by NG2 + pericytes was increased in PTK/ZK-treated versus vehicletreated tumors ( Fig. 4A and B) . The numbers of tumorinfiltrating F4/80 + macrophages were also significantly decreased in tumors of PTK/ZK treated tumors compared with controls (Fig. 4B) , indicating a process of vessel normalization as induced by most antiangiogenic treatment protocols (34) . Because VEGFR-1 activity plays an important role in monocyte recruitment, such decrease may be a PTK/ZK Does Not Affect Tumor Lymphangiogenesis Previously, PTK/ZK has been shown to inhibit the signaling activity of all three VEGFR tyrosine kinases (7). We thus examined whether PTK/ZK could attenuate VEGF-C/D-driven tumor lymphangiogenesis in Rip1-Tag2;Rip1VEGF-C and Rip1Tag2;Rip1VEGF-D doubletransgenic mice. In these mice, the transgenic expression of VEGF-C or -D in h tumor cells of Rip1Tag2 mice leads to enhanced tumor lymphangiogenesis and metastasis to lymph nodes (VEGF-C) and lymph nodes and lung (VEGF-D; refs. 28, 29) . Double-transgenic Rip1Tag2;Rip1VEGF-C and Rip1Tag2;Rip1VEGF-D mice were treated daily with PTK/ZK for 3 weeks starting at age 9 weeks, a period during which tumors exhibited dramatic volume expansion and in which peritumoral lymphatics expanded with the increasing tumor volumes (28, 29) . Analysis of the extent of peritumoral lymphangiogenesis by measuring the LYVE-1-positive circumferential lymphatics revealed no significant reduction in tumor-induced lymphangiogenesis in PTK/ ZK-treated versus vehicle-treated double-transgenic Rip1-Tag2;Rip1VEGF-C and Rip1Tag2;Rip1VEGF-D mice ( Fig. 5A and B) . However, PTK/ZK efficiently reduced tumor growth as shown by the decrease in total tumor volumes ( Fig. 1) and provoked a significant reduction of VEGFR-3 phosphorylation as determined by an ELISA assay specific for the detection of the phosphorylated, activated form of VEGFR-3 (Fig. 5C ). Consistent with this observation, daily treatment of 5-week-old Rip1VEGF-C single-transgenic mice with PTK/ZK for 3 weeks did not result in reduced lymphatic vessel densities in the periphery of islets of Langerhans (data not shown), although during this time frame lymphangiogenesis is active in these mice (28) .
Macrometastases and micrometastases to the lymph node or the lung are only detectable beyond age 12 weeks of Rip1Tag2;Rip1VEGF-D double-transgenic mice, just before the mice have to be sacrificed to avoid complications by hypoglycemia. Hence, a treatment period between 9 and 12 weeks covers a time window at which most of the metastatic spread of tumor cells via the lymphatics occurs (28, 29) . To evaluate the effect of PTK/ZK treatment on metastasis to the lymph nodes and lungs of Rip1Tag2;Rip1-VEGF-D double-transgenic mice, the mice were treated for 3 weeks with either PTK/ZK or PEG300 control starting at age 9 weeks. As shown in Fig. 5D , the incidence of lymph node and lung metastasis was unaffected by the treatment. These results indicate that, in our experimental mouse models, tumor lymphangiogenesis and metastasis cannot be abrogated by PTK/ZK-mediated VEGFR-3 (and VEGFR-1 and -2) inhibition.
To corroborate the inability of PTK/ZK to repress VEGF-C-induced tumor lymphangiogenesis in Rip1Tag2;Rip1-VEGF-C double-transgenic mice, we employed adenoviral expression of a soluble VEGFR-3 construct (sFlt-4), where the three extracellular immunoglobulin domains of VEGFR-3 have been fused to a mouse immunoglobulin Fc domain (30) . This treatment regimen only caused a marginal, nonsignificant reduction of tumor lymphangiogenesis in Rip1Tag2;Rip1VEGF-C double-transgenic mice (Fig. 6A) .
In contrast, as reported previously, adenoviral expression of soluble VEGFR3 in Rip1Tag2;NCAM À/À mice significantly repressed tumor lymphangiogenesis induced by the up-regulation of endogenous VEGF-C and -D expression in Rip1Tag2;NCAM À/À mice (30) . In these mice, PTK/ZK treatment resulted in a moderate, yet nonsignificant repression of tumor-associated lymphangiogenesis. However, the presence of tumor cell clusters in lymphatic vessels was completely abrogated by the treatment with PTK/ZK (Fig. 6B) .
Together, the results show that tumor lymphangiogenesis, forced by the continuous transgenic expression of either VEGF-C or VEGF-D during Rip1Tag2 tumorigenesis in Rip1Tag2;Rip1VEGF-C and Rip1Tag2;Rip1VEGF-D double-transgenic mice, is hardly repressed by interfering VEGF-C/D-mediated VEGFR-3 signaling. In contrast, stochastic tumor lymphangiogenesis, as observed by the up-regulation of endogenous VEGF-C and -D expression in NCAM-deficient Rip1Tag2 mice, can be repressed at moderate and significant levels by PTK and the adenoviral expression of soluble VEGFR-3, respectively.
Discussion
Together, our experiments with the various Rip1Tag2 mouse models of tumor angiogenesis and tumor lymphangiogenesis show that the receptor tyrosine kinase inhibitor PTK/ZK efficiently represses tumor growth by attenuating tumor-induced blood vessel angiogenesis. Even in a 1-week treatment of 12-week-old Rip1Tag2 transgenic mice, notably at the final stages of tumor progression, a clear reduction in total tumor volumes was detectable, showing that also at later stages of tumor progression VEGF-A-driven angiogenesis is still a valuable target for restraining tumor growth.
Because PTK/ZK inhibits all three VEGFR tyrosine kinases in vitro, VEGF-C/D-induced tumor lymphangiogenesis mediated by VEGFR-3 activation should also be efficiently repressed by PTK/ZK treatment. Yet, in Rip1Tag2;Rip1-VEGF-C and Rip1Tag2;Rip1VEGF-D double-transgenic mice, where tumor lymphangiogenesis is induced by the transgenic expression of high levels of VEGF-C and -D, respectively, inhibition of VEGFR signaling by PTK/ZK has been unable to efficiently block lymphangiogenesis. In contrast, stochastic tumor lymphangiogenesis, as observed by the expression of endogenous VEGF-C and -D in Rip1Tag2;NCAM À/À mice, was efficiently repressed by soluble VEGFR-3 (30) and moderately diminished by PTK/ ZK (shown here). Our observations contrast in part with those of previous publications, where various experimental models of regenerative and inflammatory lymphangiogenesis and tumor lymphangiogenesis with subsequent lymph node metastasis have been employed to effectively inhibit lymphangiogenesis by the use of soluble VEGFR-3 immunoglobulin, small interfering RNA-mediated depletion of VEGF-C expression, neutralizing antibodies against VEGFR-3, and various pharmacologic inhibitors against VEGFR activities (see Introduction). These models interfere with lymphangiogenesis either directly at or shortly after the onset of lymphangiogenesis in regenerative, inflammatory, or tumorigenic conditions, and their experimental setting may thus differ from the models used here, where ongoing tumor lymphangiogenesis has been targeted. Notably, the results presented here also indicate that the time of onset and the levels of expression of the lymphangiogenic factors VEGF-C and -D are critical variables in defining the efficacy of antilymphangiogenic therapy by either soluble receptor constructs or pharmacologic inhibitors.
Moreover, our data raise the intriguing possibility that established and actively ongoing lymphangiogenesis, the maintenance of tumor lymphangiogenesis, may no longer be dependent on VEGFR-3 signaling, which is in line with a previous publication, where anti-VEGFR-3 treatment in newborn mice is only effective within the first 2 weeks of age, and lymphangiogenesis becomes VEGF-C independent at later time points (36) . We therefore speculate that other signaling pathways replace VEGFR signaling at later stages of tumor lymphangiogenesis. Such switch from one angiogenic growth factor system to another is not without precedence in tumor blood vessel angiogenesis: persistent inhibition of VEGF-A-mediated signaling has resulted in the emergence of therapy resistance and a switch to fibroblast growth factors and platelet-derived growth factor-mediated angiogenic signaling pathways (27, 32) . Preliminary experiments employing soluble fibroblast growth factor receptor constructs did not reveal a function for fibroblast growth factors in this process (data not shown). Therefore, attenuating pre-established and ongoing tumor lymphangiogenesis and metastasis may require other therapeutic approaches than those that target exclusively VEGFR-3 signaling.
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